Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × brigatinib × Clear all

NCT05100069 2026-03-17

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT05721950 2026-02-18

Brilliant

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04223596 2026-02-04

CUBIK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05200481 2025-11-17

MP-ALK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04074993 2023-09-28

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02706626 2023-01-26

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Phase 2 Terminated

32 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

NCT05361564 2022-05-04

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT01449461 2021-08-17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Phase 1/2 Completed

137 enrolled 38 charts

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic

NCT02094573 2021-03-15

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 2 Completed

222 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

No longer available

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell